HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: A randomized controlled trial

17Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.

Abstract

Summary Hepatitis C virus (HCV) vaccines may be able to increase viral clearance in combination with antiviral therapy. We analysed viral dynamics and HCV-specific immune response during retreatment for experienced patients in a phase Ib study with E1E2MF59 vaccine. Seventy-eight genotype 1a/1b patients [relapsers (30), partial responders (16) and nonresponders (32) to interferon-(IFN)/ribavirin-(RBV)] were randomly assigned to vaccine (V:23), Peg-IFNα2a-180-ug/qw and ribavirin 1000-1200-mg/qd for 48 weeks (P/R:25), or their combination (P/R + V:30). Vaccine (100 μg/0.5 mL) was administered intramuscularly at week 0-4-8-12-24-28-32-36. Neutralizing of binding (NOB) antibodies and lymphocyte proliferation assay (LPA) for E1E2-specific-CD4 + T cells were performed at week 0-12-16-48. Viral kinetics were analysed up to week 16. The vaccine was safe, and a sustained virological response (SVR) was achieved in 4 P/R + V and 2 P/R patients. Higher SVR rates were observed in prior relapsers (P/R + V = 27.3%; P/R = 12.5%). Higher NOB titres and LPA indexes were found at week 12 and 16 in P/R + V as compared to P/R patients (P = 0.023 and 0.025, P = 0.019 and <0.001, respectively). Among the 22 patients with the strongest direct antiviral effects of IFN (ε ≥ 0.800), those treated with P/R + V (10) reached lower HCV-RNA levels (P = 0.026) at week 16. HCV E1E2MF59 vaccine in combination with Peg-IFNα2a + RBV was safe and elicited E1E2 neutralizing antibodies and specific CD4 + T cell proliferation. Upon early response to IFN, vaccinations were associated with an enhanced second phase viral load decline. These results prompt phase II trials in combination with new antiviral therapies. © 2013 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.

References Powered by Scopus

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy

1968Citations
N/AReaders
Get full text

Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients

1287Citations
N/AReaders
Get full text

Replication of hepatitis C virus

1159Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Hepatitis C virus: Virology, diagnosis and treatment

137Citations
N/AReaders
Get full text

Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies

53Citations
N/AReaders
Get full text

Viral evasion and challenges of hepatitis C virus vaccine development

38Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Colombatto, P., Brunetto, M. R., Maina, A. M., Romagnoli, V., Almasio, P., Rumi, M. G., … Bonino, F. (2014). HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: A randomized controlled trial. Journal of Viral Hepatitis, 21(7), 458–465. https://doi.org/10.1111/jvh.12163

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

55%

Researcher 8

26%

Professor / Associate Prof. 4

13%

Lecturer / Post doc 2

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 17

49%

Biochemistry, Genetics and Molecular Bi... 10

29%

Pharmacology, Toxicology and Pharmaceut... 4

11%

Agricultural and Biological Sciences 4

11%

Save time finding and organizing research with Mendeley

Sign up for free